The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19
Open accessAbstract
This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment. All safety endpoints were met with no adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients' clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) increase of 192% (P < 0.001). Laboratory values revealed significant improvements in absolute neutrophil count [mean reduction 32% (P value <0.001)] and lymphopenia with average CD3+, CD4+, and CD8+ lymphocyte counts increasing by 46% (P < 0.05), 45% (P < 0.05), and 46% (P < 0.001), respectively. Likewise, acute phase reactants declined, with mean C-reactive protein, ferritin, and D-dimer reduction of 77% (P < 0.001), 43% (P < 0.001), and 42% (P < 0.05), respectively. In conclusion, owing to its safety profile, capacity to restore oxygenation, downregulate cytokine storm, and reconstitute immunity, ExoFlo is a promising therapeutic candidate for severe COVID-19. Future randomized controlled trials (RCTs) are needed to determine ExoFlo therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0498-4 · Cited by 175
RetractedYang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Current knowledge on exosome biogenesis and release
Hessvik, N. P., & Llorente, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2595-9 · Cited by 2,362
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., Salto-Tellez, M., Timmers, L., Lee, C. N., El Oakley, R. M., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.12.003 · Cited by 2,215
COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome
Gattinoni, L., Coppola, S., Cressoni, M., Busana, M., Rossi, S., & Chiumello, D. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0817le · Cited by 1,396
Cited by
The roles of extracellular vesicles in the immune system
Buzas, E. I. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00763-8 · Cited by 1,220
Exosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W.-S., Chen, C.-A., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 604
Mesenchymal stromal/stem cell (MSC)-Derived exosomes in clinical trials
Lotfy, A., AboQuella, N. M., & Wang, H. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03287-7 · Cited by 482
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Huang, L., Rong, Y., Tang, X., Yi, K., Qi, P., Hou, J., Liu, W., He, Y., Gao, X., Yuan, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01515-x · Cited by 401
Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Cheng, L., Li, H., Li, L., Liu, C., Yan, S., Chen, H., & Li, Y. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23618 · Cited by 387
Advances in mesenchymal stem cell exosomes: a review
Tang, Y., Zhou, Y., & Li, H.-J. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02138-7 · Cited by 327
Extracellular vesicles: a rising star for therapeutics and drug delivery
Du, S., Guan, Y., Xie, A., Yan, Z., Gao, S., Li, W., Rao, L., Chen, X., & Chen, T. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01973-5 · Cited by 314
Dabrowska, S., Andrzejewska, A., Janowski, M., & Lukomska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591065 · Cited by 282
Gimona, M., Brizzi, M. F., Choo, A. B. H., Dominici, M., Davidson, S. M., Grillari, J., Hermann, D. M., Hill, A. F., de Kleijn, D., Lai, R. C., et al. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.01.001 · Cited by 271
Current Knowledge on Exosome Biogenesis, Cargo-Sorting Mechanism and Therapeutic Implications
Xie, S., Zhang, Q., & Jiang, L. (2022) · Membranes · doi:10.3390/membranes12050498 · Cited by 262
Markov, A., Thangavelu, L., Aravindhan, S., Zekiy, A. O., Jarahian, M., Chartrand, M. S., Pathak, Y., Marofi, F., Shamlou, S., & Hassanzadeh, A. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02265-1 · Cited by 257
RetractedInhalable dry powder mRNA vaccines based on extracellular vesicles
Popowski, K. D., Moatti, A., Scull, G., Silkstone, D., Lutz, H., López de Juan Abad, B., George, A., Belcher, E., Zhu, D., Mei, X., et al. (2022) · Matter · doi:10.1016/j.matt.2022.06.012 · Cited by 218
Nguyen, D. D., & Lai, J.-Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.134970 · Cited by 178
Extracellular Vesicles in Blood: Sources, Effects, and Applications
Alberro, A., Iparraguirre, L., Fernandes, A., & Otaegui, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158163 · Cited by 170
Different sourced extracellular vesicles and their potential applications in clinical treatments
Bahmani, L., & Ullah, M. (2022) · Cells · doi:10.3390/cells11131989 · Cited by 83
MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model
Kaspi, H., Semo, J., Abramov, N., Dekel, C., Lindborg, S., Kern, R., Lebovits, C., & Aricha, R. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02143-w · Cited by 68
Mesenchymal stem cell immunomodulation: in pursuit of controlling COVID-19 related cytokine storm
Song, N., Wakimoto, H., Rossignoli, F., Bhere, D., Ciccocioppo, R., Chen, K.-S., Khalsa, J. K., Mastrolia, I., Samarelli, A. V., Dominici, M., et al. (2021) · Stem Cells · doi:10.1002/stem.3354 · Cited by 62
Yadav, P., Vats, R., Bano, A., & Bhardwaj, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118588 · Cited by 36
Albaladejo-García, V., Morán, L., Santos-Coquillat, A., González, M. I., Ye, H., Vázquez Ogando, E., Vaquero, J., Cubero, F. J., Desco, M., & Salinas, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116381 · Cited by 32
Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles
Crum, R. J., Huckestien, B. R., Dwyer, G., Mathews, L., Nascari, D. G., Hussey, G. S., Turnquist, H. R., Alcorn, J. F., & Badylak, S. F. (2023) · Science Advances · doi:10.1126/sciadv.adf9016 · Cited by 25
Aljuhani, A., Albalawi, O., Albalawi, R., Alsalama, R., Alatawi, S., Altemani, R., Abdel‐Maksoud, M. S., & Elsherbiny, N. (2023) · Cell Biology International · doi:10.1002/cbin.12014 · Cited by 12
Didamoony, M. A., Soubh, A. A., & Ahmed, L. A. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01784-7 · Cited by 9
Metadata
- Authors
- Sengupta, V., Sengupta, S., Lazo, A., Woods, P., Nolan, A., & Bremer, N.
- Venue
- Stem Cells and Development
- Publisher
- SAGE Publications
- Published
- 2020-06-15
- Volume
- 29
- Issue
- 12
- Pages
- 747-754
- ISSN
- 1525-8165 (ISSN-L)
- 1547-3287
- 1557-8534
- OpenAlex
- W3023922995
- Cited by
- 748
- References
- 30
- FWCI
- 35.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.